- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02290613
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) (EDITA)
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment naïve patients with SSc-APAH will be included in the investigator initiated trial (IIT) to assess efficacy and safety of ambrisentan. As patients life-expectancy after diagnosis of untreated patients is only one year we put forward a screening to identify borderline PAH patients and treat them before PH manifests. Therapy with ambrisentan reached a significant improvement in SSc-IPAH patients (Galiè et al. 2008). In PAH mPAP improved about 15% due to ambrisentan (Klinger et al. 2011).
Thus, especially patients with SSc-APAH have a high need for an early diagnosis and therapy. It is important to determine factors predictive of incident SSc-APAH and PH as well as the event rate of PAH and PH occurrence. Early identification and intervention with specific modern therapies as with ambrisentan may improve hemodynamic, symptoms, exercise capacity, quality of life and outcomes in this patient population, in particular in SSc-patients of borderline-PAH. It is considered reasonable that the development of manifest APAH might be preventable in this defined population with SSc and early pulmonary vascular changes. A reliable trial testing this latter hypothesis cannot be performed without critical evidence which defines the response to medical PAH-targeted therapy in borderline-PAH and the associated disease progression of manifest PAH.
Due to the positive results in the treatment of patients with SSc-APAH, the initiation of this proof-of-concept study is justified.
Previously identified patients with borderline PAH indicated by borderline mPAP values will be included in this single centre randomized, controlled, double-blind, parallel group, proof-of-concept (PoC) phase IIa IIT. If assessments necessary for screening have already been made under the screening for PH in Systemic sclerosis trial (non-drug trial, Ethics committee of Heidelberg # S360/2009), these examinations may be used for screening for this trial, as long as they have been performed within the given time frame of the screening period.
On their first visit the patients' medical history will be obtained and physical examination will be conducted. Moreover, an electrocardiogram (ECG), laboratory testing (NT-proBNP, uric acid and other laboratory tests), echocardiography at rest and during exercise and right heart catheterization will be carried out. If patients fulfill the inclusion criteria and still suffer from borderline mPAP values they will be invited to join the study. Patients will be asked to sign the informed consent form (ICF) before the initial screening will be conducted. Randomization will be performed after a maximum of 28 days and medication or placebo will be provided. If patients have been identified within the last 6 months before baseline by right heart catheterization, the measurements are considered valid for the baseline visit to spare patients a repetition of this invasive procedure. Non-invasive measurements that are out of the time-frame have to be repeated for the study. An 1:1 oral ambrisentan: oral Placebo randomization will be performed.
Patients will be randomized into either:
- A treatment arm with ambrisentan treatment (19 patients)
- A placebo arm (19 patients will receive placebo). Safety and tolerability will be controlled at each study visit until the end of study (day 180 ± 2 weeks). If necessary, the dose will be adapted. As to common practice of the clinic, the patient will adapt the dose according to tolerability and after consultation (by phone or personally) with one of the investigators.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69126
- Thoraxclinic at the University of Heidelberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- mPAP 21-24 mmHg, TPG > 11mmHg, PAWP <15 mmHg and/or
- Exercise induced elevated mPAP-values >30 mmHg, PAWP <18 mmHg; TPG >15 mmHg, as defined in Saggar et al. (2012) without left heart or severe lung disease or systemic arterial hypertension
- Adult patients having completed his/her 18th birthday
- Patients with definite diagnosis of Systemic Sclerosis using the scleroderma criteria of the American Rheumatism Association
- SSc-disease duration >3 years
- Able to understand and willing to sign the Informed Consent Form
- Negative pregnancy test at the start of the trial and appropriate contraception throughout the study for women with child-bearing potential.
Exclusion Criteria:
- Any connective tissue diseases (CTD) other than SSc
- Pulmonary hypertension (PH) confirmed by right heart catheter (RHC) before enrolment, i.e. mPAP ≥25 mmHg at rest
- Patients presenting normal mPAP values, that is mPAP<21 mmHg at rest, ≤30 mmHg during exercise, PAWP >=15 mmHg at rest or <=18 mmHg during exercise
- Ongoing or a history of >2 weeks of continued use of therapies that are considered definitive PH treatment: endothelin receptor antagonists (ERA; e.g. bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (PDE5; e.g. sildenafil, tadalafil, vardenafil), prostanoids (e.g. epoprostenol, treprostinil, iloprost, beraprost) and soluble guanylate cyclase stimulator (e.g. Riociguat). Intermittent use of PDE5 inhibitors for male erectile dysfunction is permitted.
- Except for diuretics and corticosteroids medical treatment should not be expected to change 4 weeks prior inclusion into the study and during the entire 12-week study period.
- Known intolerance to ambrisentan or one of its excipients
- Clinically significant anemia (hemoglobin concentration of less than 75% of the lower limit of normal, LLN)
- Forced vital capacity (FVC) <60%, forced expiratory volume in first second (FEV1) <65%
- Severe interstitial lung disease, idiopathic pulmonary fibrosis
- Renal insufficiency (glomerular filtration rate [GFR] <60 mL/min/1.73m2 for at least 3 months)
- Baseline values of hepatic aminotransferases (ALT and/or AST) >3 x upper limit of normal (ULN)
- Systolic blood pressure <85 mmHg;
- evidence of inadequately treated blood pressure >160/90 mmHg and/or blood pressure during exercise >220/120 mmHg
- Patients referred with clinically significant overt heart failure
- Clinically significant fluid retention
- Previous evidence or diagnosis of clinically relevant left heart disease, i.e. at least one of the following: Previous echocardiography with estimated left ventricular (LV) ejection fraction <50%, previous history of cardiogenic pulmonary edema, increased size of left atrium (>50 mm)
- Known significant diastolic dysfunction associated with clinical heart failure
- Known coronary disease or significant valvular heart disease
- Known congenital heart defects such as single ventricle, transposition, Eisenmenger
- Known hypertrophic cardiomyopathy or left ventricular hypertrophy (interventricular septum thickness (IVS) or posterior wall thickness (PWD) >1.2 cm)
- Participation in any clinical drug trial within 4 weeks prior to screening of this study and/or who is scheduled to receive another investigational medicinal product (IMP) during the course of this study
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo tablet
|
Placebo tablet (one to two tablets corresponding to one to two verum tablets)
Other Names:
|
Experimental: Ambrisentan Verum
Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
|
Titration: As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators. Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented. Maximum dose allowed: not to exceed 10 mg/day. Administration: Ambrisentan and placebo will be administered orally with or without food intake.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Pulmonary Arterial Pressure Change From Baseline
Time Frame: baseline, 6 months
|
Determine whether mean pulmonary arterial pressure of SSc patients with borderline - PAH (mPAP 21 24 mmHg, TPG >11 mmHg) can be reduced by 3 mm Hg (absolute change baseline vs. 6 months; equals 15%) following treatment with ambrisentan 10 mg/die (initiated with 5 mg/die and elevated up to 10 mg/die) over 6 months (primary endpoint) compared to baseline and placebo.
|
baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Pulmonary Arterial Pressure During Exercise Change From Baseline
Time Frame: baseline, 6 months
|
Determine whether exercise induced elevated mean pulmonary arterial pressure-values (>30 mmHg without left heart or severe lung disease or systemic arterial hypertension) can be reduced by ambrisentan 10 mg/die over 6 months.
|
baseline, 6 months
|
6-Minute-walking Test
Time Frame: baseline, 6 months
|
baseline, 6 months
|
|
Borg Dyspnea Index
Time Frame: baseline, 6 months
|
measured directly after 6 minute walking distance; The Borg dyspnea index is an standardized scale which reports the subjective feeling of exertion from 0 (no dyspnea) to 10 (maximal feeling of dyspnea).
|
baseline, 6 months
|
Quality of Life (SF-36) Questionnaire
Time Frame: baseline, 6 months
|
SF-36 Questionnaire; physical Summation score; All scores and subscores of the SF-36 questionnaire range from 0 (low quality of life) to 100 (high quality of life).
The physical Summation score is a compound score including the physical dimensions of the SF-36.
|
baseline, 6 months
|
Lung Function
Time Frame: baseline,6 months
|
DLCo (diffusing capacity or transfer factor of the lung for carbon monoxide (CO))
|
baseline,6 months
|
Lung Function
Time Frame: baseline, 6 months
|
DLCo (diffusing capacity or transfer factor of the lung for carbon monoxide (CO))
|
baseline, 6 months
|
Lung Function
Time Frame: baseline, 6 months
|
FVC (forced vital capacity)
|
baseline, 6 months
|
Lung Function
Time Frame: baseline, 6 months
|
FEV1 (forced expiratory volume in one second)
|
baseline, 6 months
|
Lung Function
Time Frame: baseline, 6 months
|
TLC (total lung capacity)
|
baseline, 6 months
|
Lung Function
Time Frame: baseline, 6 months
|
residual volume
|
baseline, 6 months
|
Echocardiography
Time Frame: baseline, 6 months
|
RA-area (right atrial area)
|
baseline, 6 months
|
Echocardiography
Time Frame: baseline, 6 months
|
RV-area (right ventricular area)
|
baseline, 6 months
|
Echocardiography
Time Frame: baseline, 6 months
|
TAPSE (tricuspid annular plane systolic excursion)
|
baseline, 6 months
|
Echocardiography
Time Frame: baseline, 6 months
|
sPAP (systolic pulmonary arterial pressure)
|
baseline, 6 months
|
WHO-functional Class
Time Frame: baseline
|
The World Health Organization functional class includes four categories with
|
baseline
|
Hemodynamics
Time Frame: change from baseline to 6 months
|
right atrial pressure
|
change from baseline to 6 months
|
Hemodynamics
Time Frame: baseline, 6 months
|
pulmonary vascular resistance
|
baseline, 6 months
|
Hemodynamics
Time Frame: baseline, 6 months
|
cardiac output (CO)
|
baseline, 6 months
|
Hemodynamics
Time Frame: baseline, 6 months
|
cardiac index (CI)
|
baseline, 6 months
|
Hemodynamics
Time Frame: baseline , 6 months
|
PAWP (pulmonary arterial wedge pressure)
|
baseline , 6 months
|
Hemodynamics
Time Frame: baseline, 6 months
|
venous oxygen saturation (SvO2)
|
baseline, 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ekkehard Grünig, MD, Thoraxclinic at the University of Heidelberg
Publications and helpful links
General Publications
- Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10;117(23):3010-9. doi: 10.1161/CIRCULATIONAHA.107.742510. Epub 2008 May 27.
- Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol. 2011 Jul 15;108(2):302-7. doi: 10.1016/j.amjcard.2011.03.037. Epub 2011 May 3.
- Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grunig E. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther. 2019 Oct 26;21(1):217. doi: 10.1186/s13075-019-1981-0.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Connective Tissue Diseases
- Sclerosis
- Hypertension
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Pulmonary Arterial Hypertension
- Hypertension, Pulmonary
- Antihypertensive Agents
- Ambrisentan
Other Study ID Numbers
- 2014-05ED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
Clinical Trials on Ambrisentan
-
GlaxoSmithKlineTerminatedHypertension, PulmonaryFrance, United States, Germany, Spain, Italy, Japan, Hungary, Russian Federation, Argentina
-
GlaxoSmithKlineCompletedHypertension, PulmonaryFrance, Netherlands, Spain, Germany, Sweden, Australia, United Kingdom, Belgium, Canada, Italy, Greece, Slovakia, Norway, Czech Republic, Denmark
-
Medical University of GrazWithdrawn
-
Soumya ChatterjeeGilead SciencesCompleted
-
Gilead SciencesCompletedPulmonary Arterial HypertensionArgentina, Brazil, Chile, Mexico
-
Gilead SciencesCompletedStudy to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.Pulmonary Arterial Hypertension
-
University of Alabama at BirminghamCompletedPulmonary Arterial HypertensionUnited States
-
Gilead SciencesCompleted
-
GlaxoSmithKlineCompletedVascular DiseaseChina
-
Gilead SciencesCompleted